[1] Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337(4):242-53.

[2] Motzer RJ, Geller NL, Tan CC, et al. Salvage chemotherapy for patients with germ cell tumors. The

Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 1991;67(5):1305-10.

[3] Germa-Lluch JR, Begent RH, Bagshawe KD. Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer 1980;42(6):850-5.

[4] Bosl GJ, Geller NL, Cirrincione C, et al. Multivari-ate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983;43(7): 3403-7.

[5] Stoter G, Sylvester R, Sleijfer DT, et al. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multi-institutional Phase III Study. Cancer Res 1987;47(10):2714-8.

[6] Birch R, Williams S, Cone A, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986;4(3):400-7.

[7] Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet 1985;1(8419):8-11.

[8] Droz JP, Kramar A, Ghosn M, et al. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer 1988;62(3):564-8.

[9] Mead GM, Stenning SP, Parkinson MC, et al. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol 1992;10(1):85-94.

[10] Toner GC, Geller NL, Lin SY, et al. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer 1991; 67(8):2049-57.

[11] Nichols CR, Saxman S, Williams SD, et al. Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience. Cancer 1990; 65(7):1641-6.

[12] Bajorin D, Katz A, Chan E, et al. Comparison of criteria for assigning germ cell tumor patients to "good risk'' and "poor risk'' studies. J Clin Oncol 1988; 6(5):786-92.

[13] International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15(2):594-603.

[14] de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19(6):1629-40.

[15] Kollmannsberger C, Nichols C, Meisner C, et al. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. Ann Oncol 2000;11(9):1115-20.

[16] Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002;20(7):1864-73.

[17] Toner GC, Geller NL, Tan C, et al. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 1990; 50(18):5904-10.

[18] Murphy BA, Motzer RJ, Mazumdar M, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994;73(10):2520-6.

[19] Motzer RJ, Mazumdar M, Gulati SC, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993;85(22):1828-35.

[20] de Wit R, Collette L, Sylvester R, et al. Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 1998; 78(10):1350-5.

[21] Toner GC. Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use. J Clin Oncol 2004;22(19):3842-5.

[22] Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminoma-tous germ cell tumors. J Clin Oncol 2004;22(19): 3868-76.

[23] Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316(23):1435-40.

[24] Williams SD, Birch R, Greco FA, et al. Comparison of cisplatin + bleomycin + either vinblastine or VP-16 in disseminated testicular cancer: a preliminary report. Prog Clin Biol Res 1984;153:219-23.

[25] Samson MK, Rivkin SE, Jones SE, et al. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer 1984; 53(5):1029-35.

[26] Ozols RF, Ihde DC, Linehan WM, et al. A randomized trial of standard chemotherapy versus a highdose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988;6(6):1031-40.

[27] Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study

Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9(7):1163-72.

[28] Loehrer PJ Sr., Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109(7):540-6.

[29] Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16(4):1287-93.

[30] Wozniak AJ, Samson MK, Shah NT, et al. A randomized trial of cisplatin, vinblastine, and bleomy-cin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 1991;9(1):70-6.

[31] de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non- seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995;71(6):1311-4.

[32] Lewis CR, Fossa SD, Mead G, et al. BOP/VIP— a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 1991;2(3):203-11.

[33] Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/ European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16(2):692-701.

[34] Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997;8(5):477-83.

[35] Bower M, Brock C, Holden L, et al. POMB/ACE chemotherapy for mediastinal germ cell tumours. Eur J Cancer 1997;33(6):838-42.

[36] Germa-Lluch JR, Garcia del Muro X, Tabernero JM, et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience. Ann Oncol 1999;10(3):289-93.

[37] Horwich A, Mason M, Fossa SD, et al. Accelerated induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis metastatic germ cell tumours. Proc Am Soc Clin Oncol 1997;16:319a.

[38] Christian JA, Huddart RA, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003;21(5):871-7.

[39] Decatris MP, Wilkinson PM, Welch RS, et al. Highdose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 2000;11(4):427-34.

[40] Fizazi K, Prow DM, Do KA, et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 2002;86(10):1555-60.

[41] Fossa SD, Paluchowska B, Horwich A, et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer 2005; 93(11):1209-14.

[42] Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003;21(22): 4083-91.

[43] Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autolo-gous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13(6):1328-35.

[44] Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxic-ity. J Clin Oncol 1996;14(4):1098-105.

[45] Broun ER, Nichols CR, Turns M, et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994;73(6):1716-20.

[46] Motzer RJ, Mazumdar M, Bajorin DF, et al. Highdose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol 1997;15(7):2546-52.

[47] Droz JP, Pico JL, Ghosn M, et al. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. Bull Cancer 1992;79(5):497-507.

[48] Barnett MJ, Coppin CM, Murray N, et al. Highdose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours. Br J Cancer 1993;68(3):594-8.

[49] Droz JP, Pico JL, Biron P, et al. No evidence of a benefit of early intensified chemotherapy with au-tologous bone marrow transplantation in first line treatment of poor risk non seminomatous germ cell tumors: preliminary results of a randomized trial. Proc Am Soc Clin Oncol 1992;11:197.

[50] Bajorin DF, Nichols CR, Margolin KA, et al. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors patients: a cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG,

SWOG, and CALGB. Proc Am Soc Clin Oncol 2006;24:4510A.

[51] Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16(2):716-24.

[52] Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11(2):324-9.

[53] deMent SH, Eggleston JC, Spivak JL. Association between mediastinal germ cell tumors and hemato-logic malignancies. Report of two cases and review of the literature. Am J Surg Pathol 1985;9(1):23-30.

[54] Nichols CR, Hoffman R, Einhorn LH, et al. Hemato-logic malignancies associated with primary mediasti-nal germ-cell tumors. Ann Intern Med 1985;102(5): 603-9.

[55] Nichols CR, Heerema NA, Palmer C, et al. Klinefel-ter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol 1987;5(8):1290-4.

[56] Dexeus FH, Logothetis CJ, Chong C, et al. Genetic abnormalities in men with germ cell tumors. J Urol 1988;140(1):80-4.

[57] Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonsemi-nomatous germ cell tumors: the Indiana university experience. J Clin Oncol 1994;12(7):1390-3.

[58] Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14(10):2638-45.

[59] Motzer RJ, Bosl GJ. Chemotherapy for germ cell tumors. Urol Clin North Am 1987;14(2):389-98.

[60] Vuky J, Bains M, Bacik J, et al. Role of postchemo-therapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum. J Clin Oncol 2001;19(3):682-8.

[61] Kay PH, Wells FC, Goldstraw P. A multidisciplin-ary approach to primary nonseminomatous germ cell tumors of the mediastinum. Ann Thorac Surg 1987;44(6):578-82.

[62] Vogelzang NJ, Raghavan D, Anderson RW, et al. Mediastinal nonseminomatous germ cell tumors: the role of combined modality therapy. Ann Thorac Surg 1982;33(4):333-9.

[63] Fossa SD, Bokemeyer C, Gerl A, et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 1999;85(4):988-97.

[64] Rivoire M, Elias D, De Cian F, et al. Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 2001; 92(3):578-87.

[65] Collette L, Sylvester RJ, Stenning SP, et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma.

European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 1999;91(10):839-46.

[66] Feuer EJ, Sheinfeld J, Bosl GJ. Does size matter? Association between number of patients treated and patient outcome in metastatic testic-ular cancer. J Natl Cancer Inst 1999;91(10): 816-8.

Urol Clin N Am 34 (2007) 199-217

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment